DE602006010602D1 - Benzimidazolderivate und ihre verwendung zur modulierung des gabaa-rezeptorkomplexes - Google Patents

Benzimidazolderivate und ihre verwendung zur modulierung des gabaa-rezeptorkomplexes

Info

Publication number
DE602006010602D1
DE602006010602D1 DE602006010602T DE602006010602T DE602006010602D1 DE 602006010602 D1 DE602006010602 D1 DE 602006010602D1 DE 602006010602 T DE602006010602 T DE 602006010602T DE 602006010602 T DE602006010602 T DE 602006010602T DE 602006010602 D1 DE602006010602 D1 DE 602006010602D1
Authority
DE
Germany
Prior art keywords
receptor complex
benzimidazole derivatives
gabaa receptor
modulating
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006010602T
Other languages
English (en)
Inventor
Janus S Larsen
Lene Teuber
Philip K Ahring
Elsebet Oestergaard Nielsen
Naheed Mirza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Publication of DE602006010602D1 publication Critical patent/DE602006010602D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE602006010602T 2005-12-05 2006-12-04 Benzimidazolderivate und ihre verwendung zur modulierung des gabaa-rezeptorkomplexes Active DE602006010602D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200501719 2005-12-05
US74253505P 2005-12-06 2005-12-06
DKPA200601326 2006-10-12
US85129106P 2006-10-13 2006-10-13
PCT/EP2006/069237 WO2007065864A1 (en) 2005-12-05 2006-12-04 Benzimidazole derivatives and their use for modulating the gabaa receptor complex

Publications (1)

Publication Number Publication Date
DE602006010602D1 true DE602006010602D1 (de) 2009-12-31

Family

ID=37873123

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006010602T Active DE602006010602D1 (de) 2005-12-05 2006-12-04 Benzimidazolderivate und ihre verwendung zur modulierung des gabaa-rezeptorkomplexes

Country Status (14)

Country Link
US (1) US7923464B2 (de)
EP (1) EP1996556B1 (de)
JP (1) JP2009518292A (de)
KR (1) KR20080077620A (de)
AT (1) ATE449077T1 (de)
AU (1) AU2006324046A1 (de)
CA (1) CA2632395A1 (de)
DE (1) DE602006010602D1 (de)
DK (1) DK1996556T3 (de)
ES (1) ES2335438T3 (de)
IL (1) IL189974A0 (de)
NO (1) NO20083045L (de)
PL (1) PL1996556T3 (de)
WO (1) WO2007065864A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI391381B (zh) 2006-03-24 2013-04-01 Neurosearch As 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途
EP2231617A1 (de) * 2007-12-21 2010-09-29 Wyeth LLC Benzimidazolverbindungen
CN102036952A (zh) * 2008-04-16 2011-04-27 比奥里波克斯公司 用作药物的双芳基化合物
WO2010039668A2 (en) * 2008-10-01 2010-04-08 The Regents Of The University Of California Inhibitors of cyclin kinase inhibitor p21
WO2010055127A1 (en) * 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
WO2010055125A1 (en) * 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK40192D0 (da) 1992-03-26 1992-03-26 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
CZ287545B6 (en) 1995-04-21 2000-12-13 Neurosearch As Benzimidazole derivatives, pharmaceutical preparation in which they are comprised and their use
JP2001502675A (ja) 1996-10-21 2001-02-27 ニューロサーチ・アクティーゼルスカブ １―フエニル―ベンズイミダゾール化合物及びこれをｂａｇａ▲下ａ▼―レセプターモデュレーターとして使用する方法
WO1999019323A1 (en) 1997-10-10 1999-04-22 Neurosearch A/S Benzimidazole compounds, pharmaceutical compositions containing the compounds and their use
WO2000078728A1 (en) 1999-06-22 2000-12-28 Neurosearch A/S Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
WO2002050057A1 (en) 2000-12-20 2002-06-27 Neurosearch A/S Novel benzimidazole derivatives for the treatment of gaba-alpha mediated disorders
EP1613618A2 (de) 2003-04-03 2006-01-11 Neurosearch A/S Benzimidazol derivate und ihre verwendung als modulatoren des gaba-a rezeptoren komplexes
US7335777B2 (en) * 2003-04-03 2008-02-26 Neurosearch A/S Benzimidazole derivatives and their use for modulating the GABAA receptor complex
AP2006003549A0 (en) 2003-08-21 2006-04-30 Osi Pharm Inc N-substituted benzimidazolyl C-kit inhibitors.
JP2007509108A (ja) 2003-10-23 2007-04-12 アクゾ ノベル ナムローゼ フェンノートシャップ １，５，７−三置換ベンズイミダゾール誘導体及びｇａｂａａ受容体複合体を調節するためのその使用
BRPI0518794A2 (pt) 2004-12-01 2008-12-09 Osi Pharm Inc composto, composiÇço, mÉtodo de tratamento de distérbio hiperproliferativo, e, biblioteca combinatorial
EP1877052B1 (de) 2005-04-13 2009-07-22 Neurosearch A/S Benzimidazolderivate und deren verwendung zur modulation des gabaa-rezeptorkomplexes
EP1874758A1 (de) * 2005-04-19 2008-01-09 Neurosearch A/S Benzimidazol-derivate und ihre verwendung zur modulierung des gabaa-rezeptor-komplexes
TWI391381B (zh) 2006-03-24 2013-04-01 Neurosearch As 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途

Also Published As

Publication number Publication date
EP1996556A1 (de) 2008-12-03
EP1996556B1 (de) 2009-11-18
KR20080077620A (ko) 2008-08-25
PL1996556T3 (pl) 2010-05-31
WO2007065864A1 (en) 2007-06-14
NO20083045L (no) 2008-09-04
IL189974A0 (en) 2008-08-07
JP2009518292A (ja) 2009-05-07
US20090048321A1 (en) 2009-02-19
US7923464B2 (en) 2011-04-12
ATE449077T1 (de) 2009-12-15
AU2006324046A1 (en) 2007-06-14
ES2335438T3 (es) 2010-03-26
DK1996556T3 (da) 2010-04-06
CA2632395A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
EA201001371A1 (ru) Конденсированные пиримидиноновые соединения как модуляторы trpv3
NO20093009L (no) Kondensert ring heterocykel kinase modulatorer
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
NO20076413L (no) Multisykliske forbindelser og fremgangsmater for deres anvendelse
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
SE0302232D0 (sv) Novel Compounds
GEP20084550B (en) Substituted morpholine compounds for the treatment of central nervous system disorders
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MX2009003981A (es) Agentes moduladores del receptor de calcio.
WO2007042544A3 (en) Imidazole derivatives and their use for modulating the gabaa receptor complex
EA200801302A1 (ru) Композиции и способы лечения нарушений цнс
MX2009006170A (es) Compuestos y composiciones como inhibidores de cinasa.
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
ATE449077T1 (de) Benzimidazolderivate und ihre verwendung zur modulierung des gabaa-rezeptorkomplexes
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
EA201000675A1 (ru) Производные хромана как модуляторы trpv3
EA201190086A1 (ru) Сочлененные производные имидазола в качестве антагониста trpv3
MX2007012624A (es) Derivados de benzimidazol y su uso para la modulacion del complejo del receptor gaba-a.
ATE407119T1 (de) Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors
ATE544344T1 (de) Therapeutische pyrazolochinolinderivate
TW200740766A (en) Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands
WO2004087690A3 (en) Benzimidazole derivatives and their use for modulating the gaba-a receptor complex
UA104861C2 (uk) Похідні хроману як модулятори trpv3
ATE386519T1 (de) Benzimidazole derivate und ihre anwendung als gaba a rezeptor komplex modulatoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition